Sulfonamide derivatives for the treatment of diseases

A pharmaceutical composition comprising a combination of a compound of formula (1):

• or a pharmaceutically acceptable salt, isomer, or tautomer thereof,
• wherein:
• the (CH2)n—C(═O)Q1 group is in the meta or para position;
• R1 and R2 are independently selected from H and C1-C4 alkyl;
• n is 0, 1 or 2;
• and
• Q1 is selected from:
• and *—NR8-Q2-A;
• p is 1 or 2;
• Q2 is C1-C4 alkylenyl optionally substituted with one hydroxy group;
• R8 is H or C1-C4 alkyl;
• A is pyridyl optionally substituted with OH, C3-C7 cycloalkyl optionally substituted with OH, or
• R3, R4, R5, R6 and R7 are independently H, C1-C4 alkyl, OR9, SR9, halo, CN, CF3, OCF3, COOR9, SO2NR9R10, CONR9R10, NR9R10, NHCOR10 or phenyl optionally substituted with 1 to 3 OR9, halo or C1-C4 alkyl;
• R9 and R10 are independently H or C1-C4 alkyl;
• and
• the * represents the attachment point to the carbonyl group of formula (1);
• provided that the group Q1 is substituted with at least one hydroxy group
• with a therapeutic agent selected from:
• (a) an oral or inhaled glucocorticosteroid;
• or
• (b) a muscarinic M3 receptor antagonist;
• and a pharmaceutically acceptable excipient or additive.